Accessibility Menu
Aptorum Group logo

Aptorum Group(NASDAQ) APM

This security has been delisted. This page is retained for historical reference.

Aptorum Group last closing stock price
MetricPriceDate
Last closeUSD 6.612026-09-02
Aptorum Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.74%USD 7.852026-08-26
1 month-30.93%USD 9.572026-08-03
3 month-39.36%USD 10.902026-06-04
Year to date-37.64%USD 10.602025-12-31
1 year-64.46%USD 18.602025-09-02
3 year-70.49%USD 22.402023-09-01
5 year-97.5%USD 264.002021-09-03
Since inception-99.51%USD 1,435.002018-12-18

APM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

APM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5.94%

Return on Capital

-6.84%

Return on Assets

-7.29%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$960.82K

Operating Income

-$6.34M

EBITDA

-$6.62M

Operating Cash Flow

-$4.37M

Capital Expenditure

-$43.00

Free Cash Flow

-$4.37M

Cash & ST Invst.

$1.83M

Total Debt

$3.51M

Aptorum Group Performance Analysis

Aptorum Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,295,889-15.9%
20232023-12-31USD 431,378-66.7%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Aptorum Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31-100.0%
Q22026-06-30N/A
Aptorum Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -27.45-61.6%
20232023-12-31USD -6.25-77.2%
20242024-12-31USD -7.8325.3%
20252025-12-31USD -1.85-76.3%
Aptorum Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3142.0%
Q22025-06-3078.6%
Q42025-12-31-109.7%
Q22026-06-3076.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

$1.62M

+161.4%

EBITDA

$1.41M

+160.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.83M

+134.2%

Total Debt

$3.51M

+3.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.51M

+1984.4%

Return on Assets

-7.29%

N/A

Return on Invested Capital

-2.86%

N/A

Free Cash Flow

-$1.64M

+73.7%

Operating Cash Flow

-$1.64M

+73.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADILAdial Pharmaceuticals, Inc.
$6.45+2.06%
ADXNAddex Therapeutics Ltd
$3.76+6.82%
ARDSAridis Pharmaceuticals, Inc.
$0.00+0.00%
ATHEAlterity Therapeutics Limited
$4.50-0.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.63+0.13%
SPCXSpace Exploration Technologies
$151.40+0.08%
NVDANvidia
$229.45+0.02%
BITOProShares Trust - ProShares Bitcoin ETF
$10.94+0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.